[Federal Register Volume 68, Number 186 (Thursday, September 25, 2003)]
[Rules and Regulations]
[Pages 55308-55309]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 03-23995]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 520


Oral Dosage Form New Animal Drugs; Ivermectin and Praziquantel 
Paste

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a new animal drug application 
(NADA) filed by Virbac AH, Inc. The NADA provides for use of an 
ivermectin and praziquantel oral paste for the treatment and control of 
various species of internal parasites in horses.

DATES: This rule is effective September 25, 2003.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for 
Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-7543, e-mail: 
[email protected].

[[Page 55309]]


SUPPLEMENTARY INFORMATION: Virbac AH, Inc., 3200 Meacham Blvd., Ft. 
Worth, TX 76137, filed NADA 141-215 for use of EQUIMAX (ivermectin 
1.87%/praziquantel 14.03%) Paste in horses for the treatment and 
control of various species of internal parasites. The NADA is approved 
as of July 11, 2003, and the regulations in 21 CFR 520.1198 are amended 
to reflect the approval. The basis of approval is discussed in the 
freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and 
effectiveness data and information submitted to support approval of 
this application may be seen in the Division of Dockets Management 
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, 
Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.
    Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 
3 years of marketing exclusivity beginning July 11, 2003.
    The agency has determined under 21 CFR 25.33(d)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 520

    Animal drugs.

0
Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is 
amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

0
1. The authority citation for 21 CFR part 520 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

0
2. Section 520.1198 is revised to read as follows:


Sec.  520.1198  Ivermectin and praziquantel paste.

    (a) Specifications. Each milligram (mg) of paste contains:
    (1) 0.0155 mg (1.55 percent) ivermectin and 0.0775 mg (7.75 
percent) praziquantel.
    (2) 0.0187 mg (1.87 percent) ivermectin and 0.1403 mg (14.03 
percent) praziquantel.
    (b) Sponsors. See sponsors in Sec.  510.600(c) of this chapter for 
uses as in paragraph (d) of this section.--(1) No. 050604 for use of 
product described in paragraph (a)(1) of this section as in paragraphs 
(d)(1)(i), (d)(2)(i) and (d)(3) of this section.
    (2) No. 051311 for use of product described in paragraph (a)(2) of 
this section as in paragraphs (d)(1)(ii), (d)(2)(ii), and (d)(3) of 
this section.
    (c) Special considerations. See Sec.  500.25 of this chapter.
    (d) Conditions of use in horses--(1) Amount--(i) 200 micrograms 
(mcg) per kilogram (/kg) ivermectin (91 mcg per pound (/lb)) and 1 mg/
kg praziquantel (454 mcg/lb) body weight.
    (ii) 200 mcg/kg ivermectin (91 mcg/lb) and 1.5 mg/kg praziquantel 
(681 mcg/lb) body weight.
    (2) Indications for use. For treatment and control of:
    (i) Tapeworms (Anoplocephala perfoliata); large strongyles (adults) 
(Strongylus vulgaris (also early forms in blood vessels), S. edentatus 
(also tissue stages), S. equinus; Triodontophorus spp., including T. 
brevicauda and T. serratus; and Craterostomum acuticaudatum); small 
strongyles including those resistant to some benzimidazole class 
compounds (adults and fourth-stage larvae) (Coronocyclus spp., 
including C. coronatus, C. labiatus, and C. labratus; Cyathostomum 
spp., including C. catinatum and C. pateratum; Cylicocyclus spp., 
including C. insigne, C. leptostomum, C. nassatus, and C. 
brevicapsulatus; Cylicodontophorus spp.; Cylicostephanus spp., 
including C. calicatus, C. goldi, C. longibursatus, and C. minutus; and 
Petrovinema poculatum); pinworms (adults and fourth-stage larvae) 
(Oxyuris equi); ascarids (adults and third- and fourth-stage larvae) 
(Parascaris equorum); hairworms (adults) (Trichostrongylus axei); 
large-mouth stomach worms (adults) (Habronema muscae); bots (oral and 
gastric stages) (Gasterophilus spp., including G. intestinalis and G. 
nasalis); lungworms (adults and fourth-stage larvae) (Dictyocaulus 
arnfieldi); intestinal threadworms (adults) (Strongyloides westeri); 
summer sores caused by Habronema and Draschia spp. cutaneous third-
stage larvae; and dermatitis caused by neck threadworm microfilariae, 
Onchocerca sp.
    (ii) Tapeworms (Anoplocephala perfoliata); large strongyles 
(adults) (Strongylus vulgaris (also early forms in blood vessels), S. 
edentatus (also tissue stages), S. equinus, Triodontophorus spp.); 
small strongyles including those resistant to some benzimidazole-class 
compounds (adults and fourth-stage larvae) (Cyathostomum spp., 
Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp.); 
pinworms (adults and fourth-stage larvae) (Oxyuris equi); ascarids 
(adults and third- and fourth-stage larvae) (Parascaris equorum); 
hairworms (adults) (Trichostrongylus axei); large-mouth stomach worms 
(adults) (Habronema muscae); bots (oral and gastric stages) 
(Gasterophilus spp.); lungworms (adults and fourth-stage larvae) 
(Dictyocaulus arnfieldi); intestinal threadworms (adults) 
(Strongyloides westeri); summer sores caused by Habronema and Draschia 
spp. cutaneous third-stage larvae; and dermatitis caused by neck 
threadworm microfilariae, Onchocerca sp.
    (3) Limitations. For oral use only. Do not use in horses for food 
purposes.

    Dated: September 8, 2003.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 03-23995 Filed 9-24-03; 8:45 am]
BILLING CODE 4160-01-S